mRNA vs Therapeutic Vaccine — Oncology Deal Terms Comparison

mRNA Median Upfront

$335M

Total: $2.1B

Therapeutic Vaccine Median Upfront

$297M

Total: $1.9B

mRNA Royalties

12.8%-20.9%

Tiered to 24.9%

Therapeutic Vaccine Royalties

12.3%-20.1%

Tiered to 24.1%

Model Your Deal

Market Analysis

In oncology, mRNA and Therapeutic Vaccine represent two of the most actively transacted modalities. At Phase 2, mRNA deals carry a median total deal value of $2.1B with $335M upfront, compared to $1.9B total value and $297M upfront for Therapeutic Vaccine. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.

Milestone structures diverge between the two modalities. mRNA development milestones average $448M versus $397M for Therapeutic Vaccine. Commercial milestones are $628M for mRNA and $555M for Therapeutic Vaccine. Royalty rates range from 12.8%-20.9% for mRNA and 12.3%-20.1% for Therapeutic Vaccine.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How do mRNA and Therapeutic Vaccine deal terms compare in oncology?

mRNA Phase 2 deals average $2.1B total deal value ($335M upfront), while Therapeutic Vaccine deals average $1.9B ($297M upfront). The difference reflects modality-specific risk profiles, manufacturing considerations, and competitive positioning.

Which modality commands higher royalty rates: mRNA or Therapeutic Vaccine?

mRNA base royalties range from 12.8% to 20.9%, while Therapeutic Vaccine royalties range from 12.3% to 20.1%. High-tier escalation reaches 24.9% for mRNA and 24.1% for Therapeutic Vaccine.

How do milestone structures differ between mRNA and Therapeutic Vaccine?

mRNA deals allocate $448M to development milestones vs $397M for Therapeutic Vaccine. Commercial milestones are $628M (mRNA) vs $555M (Therapeutic Vaccine), reflecting different commercialization profiles and market expectations.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included